Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | DAO | P14920 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 7/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | PDE9A | O76083 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24788997 | 0.88 | BRD4 (0.43) | BRD4DAOACHEGDABRAF | |
| SCHEMBL24788383 | 0.83 | BRD4 (0.42) | BRD4DAOACHEGDABRAF | |
| SCHEMBL24789008 | 0.80 | BRD4 (0.40) | BRD4DAOACHEGDABRAF | |
| SCHEMBL1503032 | 0.77 | BRD4 (0.48) | BRD4DAOACHEGDABRAF | |
| SCHEMBL19876224 | 0.73 | DAO (0.72) | BRD4DAOACHEGDABRAF | |
| SCHEMBL21895410 | 0.73 | AURKA (0.45) | BRD4DAOACHEGDABRAF | |
| SCHEMBL23612486 | 0.73 | BRD4 (0.44) | BRD4DAOACHEGDABRAF | |
| SCHEMBL30663492 | 0.73 | DAO (0.72) | BRD4DAOACHEGDABRAF | |
| SCHEMBL19876250 | 0.73 | DAO (0.72) | BRD4DAOACHEGDABRAF | |
| SCHEMBL16919105 | 0.73 | BRD4 (0.44) | BRD4DAOACHEGDABRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9931407-B2 | Silicon based drug conjugates and methods of using same | BLINKBIO, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| US-9221805-B2 | Preparation and methods of use for ortho-aryl 5-membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors | Spacefill Enterprises LLP (US) | 2015-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | BRD4 3709/4885DAO 1645/4885ACHE 1789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.